

Janet T. Mills  
Governor



Sara Gagne- Holmes  
Commissioner

Maine Department of Health and Human Services  
Office of MaineCare Services - Pharmacy Unit  
11 State House Station  
Augusta, Maine 04333-0011  
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)  
Fax: (207) 287-8601

## MaineCare 2024-25 Respiratory Syncytial Virus (RSV) Update

Dear Provider

October 23, 2024

Peak respiratory syncytial virus (RSV) activity typically occurs between October and March. Please find information below regarding MaineCare's coverage of nirsevimab (Beyfortus™) and palivizumab (Synagis®)

### Nirsevimab

- Available to all eligible MaineCare members through the Maine Immunization Program and Vaccine for Children Program at medical practices and birth hospitals. Nirsevimab is not covered by MaineCare.
- Recommended for infants ages birth to 8 months from October 1<sup>st</sup> to March 31<sup>st</sup> and high-risk infants, ages 8 months to 19 months per CDC guidance.

### Palivizumab

- Available for eligible high-risk infants ages birth to 24 months for whom nirsevimab is not indicated or if nirsevimab is not available as outlined on the palivizumab/Synagis prior authorization (PA) form.
  - PA form available on the [MaineCarepdl.org](https://www.mainearepdl.org/prior-authorization-forms.html) website Prior Authorization tab and via this url: <https://www.mainearepdl.org/prior-authorization-forms.html>
- PA requests for palivizumab for high-risk infants may be submitted beginning November 1, 2024 for dates of administration starting November 11, 2024.
  - PA requests will not be approved for any patient who has already received nirsevimab in the same RSV season.

For questions regarding MaineCare coverage, please contact the Optum Pharmacy Help Desk at 1-888-420-9711. Maine providers can also send inquiries via email to [MaineHD@optum.com](mailto:MaineHD@optum.com).

---

**Please distribute immediately.**

For questions regarding communications, contact the Pharmacy Provider Communications team: [pharmacyprovidercommunications@optum.com](mailto:pharmacyprovidercommunications@optum.com)  
All Optum trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without express written consent of OptumRx. ©2024 Optum, Inc. All rights reserved.